NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 11 Nov2017 (#41)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are a **selection** of **39** pre-screened, currently open health funding opportunities **in various disciplines** for which **South African institutions are eligible to apply**.*

*Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries cdevries@sun.ac.za) **to inform of your intent to apply.***

Important Notices

- **Statement on Article Publication Resulting from NIH Funded Research (NOT-OD-18-011)**
- **Reminder: FORMS-E Grant Application Forms & Instructions must be used for due dates on or after 25 January 2018 (NOT-HS-18-003)**
  - **the new FORMS-E grant application package**
  - **changes to the NIH definition of a clinical trial**

1. Mobile and Connected Health Interventions to Improve Care Continuum and Health Outcomes among Youth with HIV

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-MH-18-605) **Type:** ***R34***
Application Due Date: 9 January 2018. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks to develop and test the next generation of interventions delivered through mobile health (mHealth) technology to improve diagnosis, linkage to care, retention in care, and viral suppression among youth living with human immunodeficiency virus (YLWH). This FOA supports planning for a clinical trial and can include a small pilot clinical trial that a) incorporates emerging and cutting edge technologies to enhance outcomes along the HIV care continuum, b) supports real-time clinical decision making, and c) facilitates effective long-term management of HIV. Critical to this FOA, proposed research should identify specific patient outcomes along the HIV care continuum that are expected to improve from technological approaches.
Budget: NIMH intends to fund an estimate of 4-6 awards, corresponding to a total of $2,000,000, for fiscal year 2018. Future year amounts will depend on annual appropriations. NIDA intends to fund an estimate of 4-6 awards corresponding to a total of $2,000,000 for FY2018. Direct costs limited to $225,000 per year and $450,000 over the 3-year project period. The scope of the proposed project should determine the project period. The project period is limited to 3 years.

2. Mobile and Connected Health Interventions to Improve Care Continuum and Health Outcomes among Youth with HIV

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-MH-18-606) **Type:** ***R01***
Application Due Date: 9 January 2018. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks to develop and test the next generation of interventions delivered through mobile health (mHealth) technology to improve diagnosis, linkage to care, retention in care, and viral suppression among youth living with human immunodeficiency virus (YLWH). This FOA supports clinical trials that a) incorporate emerging and cutting edge technologies to enhance outcomes along the HIV care continuum, b) support real-time clinical decision making, and c) facilitate effective long-term management of HIV. Critical to this FOA, proposed research should identify specific patient outcomes along the HIV care continuum that are expected to improve from technological approaches.
Budget: NIMH intends to fund an estimate of 4-6 awards, corresponding to a total of $2,000,000, for fiscal year 2018. Future year amounts will depend on annual appropriations. NIMHD intends to commit $1,000,000 in FY2018 to fund approximately 2-3 awards. NIDA intends to commit $2,000,000 in FY2018 to fund approximately 4-6 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-001) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. This FOA will not support phase III clinical trials.

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

4. Examination of Survivorship Care Planning Efficacy and Impact (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-002) **Type:** ***R01***
(PA-18-012) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application **R21:** The combined budget for direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

5. Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-003) **Type:** ***R01***
(PA-18-013) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE).

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application **R21:** The combined budget for direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

6. Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-004) **Type:** ***R01***
(PA-18-014) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. Observational studies should emphasize modifiable risk factors for future intervention research.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application **R21:** The combined budget for direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

7. Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-005) **Type:** ***R01***
(PA-18-015) ***R21***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems. Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** The combined budget for direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

8. Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-010) **Type:** ***R01***
(PAR-18-112) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. Applications submitted under this FOA are encouraged to include development of: novel assessment approaches; better methods to evaluate instruments; assessment tools for culturally diverse populations or various age groups, including children and older adults; improved technology or applications of existing technology; statistical methods/modeling to improve assessment and/or to correct for measurement errors or biases; methods to investigate the multidimensionality of diet and physical activity behavior through pattern analysis; or integrated measurement of diet and physical activity along with the environmental context of such behaviors.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide. **R21:** The combined budget for direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

9. Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-025) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformin's human physiologic and cellular effects that would be useful in identifying novel molecular targets.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

10. Advancing Understanding, Prevention, and Management of Infections Transmitted from Women to their Infants (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-031) **Type:** ***R01***
(PA-18-092) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** The combined budget for direct costs for the 2-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

11. Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-032) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications from institutions/organizations which propose to characterize or identify factors in early childhood (birth-24 months) that may increase or mitigate risk for obesity and/or excessive weight gain and/or to fill methodological research gaps relevant to the understanding of risk for development of obesity in children. Studies should propose research in children from birth to 24 months, although any proposed follow-up assessments, if applicable, may continue past this period. Studies may also assess factors relevant to families and/or caregivers of children from birth to 24 months. Applications should seek to fill unique research needs and involve expertise across disciplines as appropriate for the proposed research question.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

12. Characterization of the Adolescent Reproductive Transition (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-033) **Type:** ***R01***
(PA-18-045) ***R21***
(PA-18-046) ***R03***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of puberty and the trajectory of sexual development. Research using new technologies and approaches is needed to fill knowledge gaps and advance understanding of normative sexual development in both males and females. It is anticipated that the findings of studies supported by this FOA will advance knowledge of puberty and the establishment of reproductive competence.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R03:** Application budgets for up to $50,000 per year are allowed but must reflect the actual needs of the proposed project. The maximum project period is 2 years. **R21:** Application budgets may not exceed $275,000 in direct costs for the entire duration of the grant. No more than $200,000 may be requested for any single year.

13. Studies at Periviable Gestation (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-036) **Type:** ***R01***
(PA-18-053) ***R03***
(PA-18-097) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) focuses on projects that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide. **R03:** Application budgets for up to $50,000 per year are allowed but must reflect the actual needs of the proposed project. The maximum project period is 2 years. **R21:** Application budgets may not exceed $275,000 in direct costs for the entire duration of the grant. No more than $200,000 may be requested for any single year.

14. Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-038) **Type:** ***R01***
(PA-18-043) ***R21***
(PA-18-044) ***R03***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to (1) promote preclinical, translational, clinical and epidemiological research in pain medications use in children or in pregnant women to fill knowledge gaps in safe use of the pain medications in these special populations; and (2) develop effective instruments or approaches to assess and evaluate maternal and child outcomes of pain medication treatments. There is a need for data on pain medications used in children and pregnant women to be shared and made available to the scientific community for future studies and to encourage replication of findings and meeting the goal of further advancing research in this area.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** Application budgets may not exceed $275,000 in direct costs for the entire duration of the grant. No more than $200,000 may be requested for any single year. **R03:** Application budgets for up to $50,000 per year are allowed but must reflect the actual needs of the proposed project. The maximum project period is 2 years

15. Behavioral and Integrative Treatment Development Program (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-055) **Type:** ***R01***
(PA-18-073) ***R34***
(PA-18-074) ***R03***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this FOA is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, optimize combinations, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) drug abuse treatment and adherence interventions for use in primary care; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat chronic pain. Research of interest includes but is not limited to Stage II and Stage III efficacy research.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R34:** Direct costs are limited to $450,000 over a 3-year project period, with no more than $225,000 in direct costs allowed in any single year. The maximum project period is 3 years. **R03:** The combined budget for direct costs for the two year project period may not exceed $100,000. No more than $50,000 in direct costs may be requested in any single year.

16. Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-056) **Type:** ***R01***
(PA-18-075) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages Research Project Grant (R01) applications from institutions/ organizations that propose to develop non-invasive methods to support outpatient clinical trials of pharmacotherapies for Substance Use Disorders (SUDs). Clinical trials evaluating the efficacy of medications to treat SUDs are limited by two major issues: a) uncertainty in assessing the level of a subject's adherence to the trial medication regimen and b) an inability to accurately and quantitatively monitor the frequency and level of a subject's illicit drug exposure. This FOA encourages the development of systems that address at least one of these issues. Applications submitted to this opportunity should focus around an outpatient clinical trial, with or without preclinical system development studies. Applications not seeking to test a minimally invasive bioassay system in a clinical trial are not appropriate for this opportunity.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** Application budgets are limited to $275,000 in direct costs over two years with no more than $200,000 in either year.

17. The Application of Big Data Analytics to Drug Abuse Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-057) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this FOA is to encourage the application of Big Data analytics to reveal deeper or novel insights into the biological and behavioral processes associated with substance abuse and addiction. NIDA recognizes that to accelerate progress toward understanding how the human brain and behavior is altered by chronic drug use and addiction, it is vital to develop more powerful analytical methods and visualization tools that can help capture the richness of data being generated from genetic, epigenetic, molecular, proteomic, metabolomic, brain-imaging, micro-electrode, behavioral, clinical, social, services, environmental studies as well as data generated from electronic health records. Applications for this FOA should develop and/or utilize computational approaches for analyzing large, complex datasets acquired from drug addiction research. The rapid increase of technologies to acquire unprecedented amounts of neurobiological and behavioral data, and an expanding capacity to store those data, results in great opportunity to bring to bear the power of the computational methods of Big Data analytics on drug abuse and addiction
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application.

18. Prescription Drug Abuse (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-058) **Type:** ***R01***
(PA-18-076) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription

medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.

19. Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-061) **Type:** ***R01***
(PA-18-079) ***R21***
(PA-18-080) ***R03***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: Despite significant scientific advancements made in substance use disorder research over the last century, the causes and consequences of drug use in later life remain poorly understood. The intent of this funding opportunity announcement is to support innovative research that examines aspects of marijuana and prescription opioid and benzodiazepine use in adults aged 50 and older. This FOA encourages research that examines the determinants of these types of drug use and/or characterizes the resulting neurobiological alterations, associated behaviors, and public health consequences. This initiative will focus on two distinct populations of older adults: individuals with earlier onset of drug use who are now entering this stage of adult development or individuals who initiate drug use after the age of 50. Applications are encouraged to utilize broad methodologies ranging from basic science, clinical, and epidemiological approaches. The insights gleaned from this initiative are critical to our understanding of the determinants of drug use in later life, as well as its consequences in the aging brain and on behavior. This knowledge may have the potential to identify risk factors and to guide clinical practices in older populations.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. **R03:** Application budgets are limited to $50,000 in direct costs per year. The total project period may not exceed two years.

20. Prevention Research in Mid-Life Adults (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-134) **Type:** ***R01***
(PA-18-153) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.

21. Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-135) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intrauterine environment, and subsequently fetal development and the health of the newborn.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

22. Functional Wellness in HIV: Maximizing the Treatment Cascade (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-136) **Type:** ***R01***
(PA-18-154) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.

23. Alcohol Impairment of Immune Function, Host Defense and Tissue Homeostasis (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-191) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function with a goal toward improving the outcome of patients who abuse alcohol. A comprehensive understanding of alcohol-induced immune dysfunctions and the underlying mechanisms is critical for developing effective diagnostic, preventive, and treatment approaches.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

24. NIH Exploratory/Developmental Research Grant Program (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-344) **Type:** ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

Budget: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

25. NIH Research Project Grant (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-345) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. Applicants should note that some ICs (see Related Notices) only accept applications proposing mechanistic studies that meet NIH's definition of a clinical trial through this funding opportunity announcement.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

26. Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-006) **Type:** ***R01***
(PAR-18-016) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application **R21:** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.

27. Dissemination and Implementation Research in Health (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-007) **Type:** ***R01***
(PAR-18-017) ***R21***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any

year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. **R21:** Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.

28. Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-009) **Type:** ***R01***

Application Due Date: first due date for all types of applications allowed for this FOA is March 1, 2018, therafter Standard dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status. A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem. The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

29. Phenotypic and Functional Studies on FOXO3 Human Longevity Variants to Inform Potential Therapeutic Target Identification Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-026) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The focus of this Funding Opportunity Announcement (FOA) is on in vivo human studies, and in vitro studies on human cells or tissues, aimed at potential identification of therapeutic targets or and/or testing of interventions for healthy aging. Potential therapeutic targets include FOXO3 itself and upstream and downstream regulators in pathways mediated by FOXO3. The range of research areas of interest in this FOA includes studies that: 1) examine in vivo phenotypic effects of human FOXO3 variants, and/or 2) elucidate effects of these variants on cellular functions and the pathways that mediate them, and/or 3) identify and evaluate candidate therapeutic targets (e.g., target validation studies, testing of candidate compounds) for potential interventions based on FOXO3 functional pathways. Projects involving whole genome sequencing of new or existing cohorts are outside the scope of this FOA. However, targeted resequencing on a limited sample set in an existing cohort could be supported by this FOA.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

30. Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-028) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages R01 grant applications that propose to develop and implement Phase III clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.

Budget: NIH intends to fund an estimate of 8 -10 awards, corresponding to a total of $25 million for fiscal year 2018. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

31. Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementias (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-029) **Type:** ***R01***
(PAR-18-181) ***R21/R33***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement:.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

R21/R33: Application budgets are limited to $275,000 in direct costs over the 2-year R21 phase, with no more than $200,000 allowed in any year Budgets are limited to less than $500,000 annual direct costs in the R33 phase. The maximum project period is 2 years for the R21 phase and 3 years for the R33 phase.

32. Outcome Measures for Use in Treatment Trials of Individuals with Intellectual and Developmental Disabilities (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-039) **Type:** ***R01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) encourages applications from institutions/organizations that propose to develop informative outcome measures for use in clinical trials for individuals wi th intellectual and developmental disabilities (IDD). This FOA will address a significant need in the field, one that is especially apparent in efforts to

develop pharmacological treatments for these populations. This FOA will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development. Potential applicants may also be interested in the FOA "Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)."
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

33. Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the National Institute of Diabetes and Digestive and Kidney Diseases NIDDK (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-042) **Type:** ***R01***
Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks to accelerate the pace and expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within NIDDK's mission by leveraging ongoing large, multi-center clinical research studies through ancillary studies. This Funding Opportunity Announcement (FOA) invites research project applications to conduct ancillary studies to major ongoing clinical research studies, including clinical trials and prospective observational studies. Applications submitted to this FOA must propose to collect new information and/or biological samples directly from participants of the ongoing parent study, and must address new research questions that are beyond those specified in the approved protocol of the parent study and are within the scientific mission of the NIDDK. This FOA cannot be used to extend the duration of the parent study.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

34. Accelerating the Pace of Drug Abuse Research Using Existing Data (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-062) **Type:** ***R01***
Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing the innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors (defined as alcohol, tobacco, prescription and other drug) and related disorders, prevention of drug use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of drug using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of drug abuse and HIV.
Budget: Budgets are limited to under $500,000 direct costs per year and must reflect the actual needs of the proposed project.

35. Natural History of Disorders Identifiable by Screening of Newborns (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-090) **Type:** ***R01***
Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

36. Pilot Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-175) **Type:** ***R01***
Application Due Date: 5 February 2018 and then Standard dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications that propose to develop and implement Phase I or II clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD) across the spectrum from pre-symptomatic to more severe stages of disease, as well as to stimulate studies to enhance trial design and methods.
Budget: Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

37. Program for Extramural/Intramural Alcohol Research Collaborations (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-195) **Type:** ***U01***

Application Due Date: Standard dates and Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity is to encourage collaboration between alcohol researchers in the extramural community and those within the NIAAA intramural research program. The objective of this Funding Opportunity Announcement is to bring together the research expertise that, as a functioning collaborative unit, will address key alcohol-based research questions that would not otherwise be possible by the same individuals working towards similar goals in isolation. The goal of the research proposed by the collaborating investigators should address questions that advance the alcohol research field with respect to issues surrounding alcohol use disorders including dependence and the effects of alcohol on health. The NIH Intramural Scientist will be a tenured or tenure-track scientist from the NIAAA Intramural Research Program, with whom the PD/PI has made prior contact for the collaborative project.

Budget: Application budgets need to reflect actual needs of the proposed project and may not exceed $250,000 direct cost per year. These funds may only be used to support the activities within the PD(s)/PI(s) (extramural scientists) research laboratory.

38. Improving Quality of Care and Quality of Life for Persons with Alzheimers Disease and Related Dementias at the End of Life (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAS-18-030) **Type:** ***R01***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA invites applications that address clinical and translational research gaps in the study of end-of-life care needs in order to improve quality of life at the end of life of people with Alzheimer's disease and related dementias (ADRD) and their families. Research that either employs (a) secondary analysis of existing data from longitudinal cohort studies or from administrative records or (b) primary data collection for Stage I behavioral intervention development is particularly encouraged.

Budget: NIA intends to fund an estimate of 4 to 6 awards, corresponding to a total of $2.2M, for fiscal year 2017 for this FOA and its companion. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

39. HIV/AIDS High Priority Drug Abuse Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAS-18-063) **Type:** ***R01***

Application Due Date: Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institutes of Health has recently announced the HIV/AIDS research priorities for the next three to five years https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html . The goal of this Funding Opportunity Announcement (FOA) is to stimulate high priority research relevant to drug abuse and HIV/AIDS.

Budget: In FY 17 NIDA intends to fund 8-12 awards and has set aside $6M. In FY 18, NIDA intends to fund 8-12 applications and has set aside is $6M. In FY 19, NIDA intends to fund approximately 4 applications and has set aside $2M.Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application

Brief definitions of some NIH grant mechanisms: ***comprehensive list of extramural grant and cooperative agreement activity codes***

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).